文献速递关节外科

地塞米松相关高血糖与糖尿病患者全关节置换术后感染并发症无关

Dexamethasone-Associated Hyperglycemia is Not Associated With Infectious Complications After Total Joint Arthroplasty in Diabetic Patients.
PubMed 文献 · J Arthroplasty · 2024-01-14

这项回顾性队列研究利用大型国家数据库纳入2016年1月至2021年12月期间接受初次择期全膝关节或全髋关节置换的成人患者110,568例,其中31.0%(34,298例)患有糖尿病。在考虑地塞米松与晨间血糖交互作用后,地塞米松未增加糖尿病患者术后假体周围关节感染或手术部位感染的几率,反而显著降低其他术后感染的校正比值比。

要点

  • 在糖尿病患者中,地塞米松未增加术后假体周围关节感染或手术部位感染的几率。
  • 地塞米松显著降低糖尿病患者其他术后感染的校正比值比:全膝关节置换校正比值比=0.9(95%置信区间0.8至1.0,P=0.030),全髋关节置换校正比值比=0.7(95%置信区间0.6至0.9,P=0.001)。
  • 上述其他感染风险降低具体见于全膝关节置换晨间血糖110至248 mg/dL的患者和全髋关节置换晨间血糖≤172 mg/dL的患者。

核心结论

  • 本研究提供了反对因担心感染而在地糖尿病患者全关节置换术中停用地塞米松的有力证据。
  • 短疗程围手术期地塞米松降低了特定患者的感染风险。
  • 关于地塞米松的讨论应从是否适用于糖尿病患者转向如何最佳优化其使用。

研究设计与样本

  • 本研究为回顾性队列研究,使用大型国家数据库纳入2016年1月至2021年12月期间接受初次择期全膝关节置换或全髋关节置换的成人患者。
  • 共纳入110,568例全关节置换患者(全膝关节置换66.6%;全髋关节置换33.4%),其中31.0%(34,298例)患有糖尿病。
  • 比较接受围手术期地塞米松的患者与未接受者,主要终点为术后90天假体周围关节感染、手术部位感染及其他非手术部位感染(尿路感染、肺炎、脓毒症)风险。

主要发现

  • 在考虑地塞米松与晨间血糖水平交互作用的模型中,地塞米松给药在糖尿病患者中未增加术后假体周围关节感染或手术部位感染的几率。
  • 地塞米松显著降低糖尿病患者其他术后感染的校正比值比:全膝关节置换校正比值比=0.9(95%置信区间0.8至1.0,P=0.030),全髋关节置换校正比值比=0.7(95%置信区间0.6至0.9,P=0.001)。
  • 其他感染风险降低具体见于全膝关节置换晨间血糖110至248 mg/dL的患者和全髋关节置换晨间血糖≤172 mg/dL的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative infection is a devastating complication of total joint arthroplasty (TJA). Perioperative use of dexamethasone in patients who have diabetes mellitus (DM) remains controversial due to concern for increased infection risk. This study aimed to evaluate the association between dexamethasone and infection risk among patients who have DM undergoing TJA. METHODS: This was a retrospective cohort study conducted on adult patients who underwent primary, elective total knee arthroplasty (TKA) or total hip arthroplasty (THA) between January 2016 and December 2021 using a large national database. We identified 110,568 TJA patients (TKA: 66.6%; THA: 33.4%), 31.0% (34,298) of which had DM. Patients who received perioperative dexamethasone were compared to those who did not. The primary end points were the 90-day risk of postoperative periprosthetic joint infection, surgical site infection (SSI), and other non-SSI (urinary tract infection, pneumonia, sepsis). RESULTS: When modeling the association between dexamethasone exposure and study outcomes while accounting for the interaction between dexamethasone and morning blood glucose levels, dexamethasone administration conferred no increased odds of postoperative periprosthetic joint infection nor SSI in diabetics. However, dexamethasone significantly lowered the adjusted odds of other postoperative infections in diabetic patients (TKA: adjusted odds ratio = 09, 95% confidence interval = 0.8 to 1.0, P = .030; THA: adjusted odds ratio = 0.7, 95% confidence interval = 0.6 to 0.9, P = .001); specifically in patients with morning blood glucose levels between 110 to 248 mg/dL in TKA and ≤ 172 mg/dL in THA. CONCLUSIONS: This study provides strong evidence against withholding dexamethasone in diabetic patients undergoing TJA based on concern for infection. Instead, short-course perioperative dexamethasone reduced infection risk in select patients. The narrative surrounding dexamethasone should shift away from questions about whether dexamethasone is appropriate for diabetic patients, and instead focus on how best to optimize its use.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Jones IA, Wier J, Liu KC, et al. Dexamethasone-Associated Hyperglycemia is Not Associated With Infectious Complications After Total Joint Arthroplasty in Diabetic Patients. J Arthroplasty. 2024. PMID: 38220028. doi:10.1016/j.arth.2024.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。